|
|
Article: BioSeek's Amylin Deal Gets $10M For Inflammation Work.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
BioSeek Inc.'s addition of Amylin Pharmaceuticals Inc. to the partner list puts $10 million into the coffers for its own program, as the firm carries out research with Amylin on the potential of peptides against inflammatory disease.
For BioSeek, the investment represents a fair bit of cash, considering the firm has raised $19 million total since its inception in 2000, said Peter Staple, CEO of the Burlingame, Calif.-based firm. BioSeek will apply its BioMAP screening system to Amylin's polypeptide hormone library, called Phormol.
"This screening deal gives us the right to pick the top two [peptides] that we're interested in, ...